[Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020].

Autor:	Pshenichnaya NY; National Medical Research Center of Tuberculosis and Infectious Diseases.; Central Research Institute of Epidemiology., Kareva EN; Sechenov First Moscow State Medical University (Sechenov University).; Pirogov Russian National Research Medical University., Leneva IA; Mechnikov Research Institute of Vaccines and Serums., Bulgakova VA; Pirogov Russian National Research Medical University.; Central Clinical Hospital., Kravchenko IE; Kazan State Medical University., Nikolaeva IV; Kazan State Medical University., Grekova AI; Smolensk State Medical University., Ivanova AP; Kursk State Medical University., Puzyreva LV; Omsk State Medical University., Khasanova GM; Bashkir State Medical University., Orlova SN; Ivanovo State Medical Academy., Tikhonova EP; Voino-Yasenetsky Krasnoyarsk State Medical University., Petrov VA; Tsyb Medical Radiological Scientific Center - branch of the National Medical Research Center for Radiology.; Obninsk Institute for Nuclear Power Engineering., Malinin OV; Izhevsk State Medical Academy., Kolaeva NV; Sechenov First Moscow State Medical University (Sechenov University)., Volchkova EV; Sechenov First Moscow State Medical University (Sechenov University)., Kanshina NN; Sechenov First Moscow State Medical University (Sechenov University)., Chulanov VP; National Medical Research Center of Tuberculosis and Infectious Diseases.; Sechenov First Moscow State Medical University (Sechenov University).
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2021 Nov 15; Vol. 93 (11), pp. 1306-1315. Date of Electronic Publication: 2021 Nov 15.
DOI:	10.26442/00403660.2021.11.201206
Abstrakt:	Aim: An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and Methods: The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results: During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion: Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu